Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Inadequate Response”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT05335499
What this trial is testing

A Phase 2a Study of TAS5315 in Patients With Chronic Spontaneous Urticaria

Who this might be right for
Chronic Spontaneous Urticaria
Taiho Pharmaceutical Co., Ltd. 126
Large-scale testing (Phase 3)Study completedNCT01377012
What this trial is testing

Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents

Who this might be right for
Rheumatoid Arthritis
Novartis Pharmaceuticals 637
Not applicableStudy completedNCT06655714
What this trial is testing

Evaluation of Inadequate Response to Ultrasound-Guided Subacromial Corticosteroid Injection in Shoulder Impingement Syndrome

Who this might be right for
Impingement Syndrome
Beylikduzu State Hospital 72
Testing effectiveness (Phase 2)Study completedNCT00867516
What this trial is testing

Safety, Efficacy and Pharmacokinetics Study of ALD518 in Patients With Active Rheumatoid Arthritis

Who this might be right for
Arthritis, Rheumatoid
CSL Behring 127
Large-scale testing (Phase 3)Ended earlyNCT03970837
What this trial is testing

Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic (cs)/Biologic (b) Disease Modifying Anti-rheumatic Drugs (DMARDs)

Who this might be right for
Arthritis, Rheumatoid
GlaxoSmithKline 1,764
Testing effectiveness (Phase 2)Study completedNCT02047604
What this trial is testing

(C2013-0302) Safety and Efficacy of Escalating Doses of SAN-300 in Patients With Rheumatoid Arthritis

Who this might be right for
Rheumatoid Arthritis
Bausch Health Americas, Inc. 41
Post-approval studies (Phase 4)Study completedNCT01149057
What this trial is testing

RoActemra/Actemra (Tocilizumab) in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Current Non-Biologic and/or Biologic DMARDS

Who this might be right for
Rheumatoid Arthritis
Hoffmann-La Roche 145
Post-approval studies (Phase 4)Study completedNCT00336973
What this trial is testing

Evaluate Raptiva in Subjects With Chronic Moderate or Worse Plaque Psoriasis Who Have Had an Inadequate Response to an Anti-TNF Agent

Who this might be right for
Psoriasis
Genentech, Inc. 73
Large-scale testing (Phase 3)Study completedNCT00559585
What this trial is testing

Methotrexate-Inadequate Response Study

Who this might be right for
Rheumatoid Arthritis (RA)
Bristol-Myers Squibb 2,492
Testing effectiveness (Phase 2)Ended earlyNCT02609048
What this trial is testing

Study to Evaluate the Effects of Two Doses of Seladelpar (MBX-8025) in Subjects With Primary Biliary Cirrhosis (PBC)

Who this might be right for
Primary Biliary Cirrhosis (PBC)
Gilead Sciences 41
Not applicableEnded earlyNCT02166333
What this trial is testing

Study To Understand Fall Reduction and Vitamin D in You

Who this might be right for
Vitamin D DeficiencyFalls
Johns Hopkins University 688
Testing effectiveness (Phase 2)Study completedNCT02969044
What this trial is testing

Study To Assess The Efficacy And Safety Of Pf-06651600 In Subjects With Rheumatoid Arthritis With An Inadequate Response To Methotrexate

Who this might be right for
Rheumatoid Arthritis
Pfizer 70
Not applicableEnded earlyNCT04904276
What this trial is testing

Observational Study of Fostamatinib as Second Line Therapy in Adult Patients With Immune Thrombocytopenia (ITP) and Insufficient Response to a Prior Therapy

Who this might be right for
ITPImmune Thrombocytopenia
Rigel Pharmaceuticals 16
Testing effectiveness (Phase 2)Study completedNCT06340958
What this trial is testing

CLE-100 (Oral Esketamine) as an Adjunctive Treatment to Standard Antidepressants for Major Depressive Disorder

Who this might be right for
Adjunctive Treatment of Major Depressive Disorder (MDD)
Clexio Biosciences Ltd. 99
Large-scale testing (Phase 3)Study completedNCT03104400
What this trial is testing

A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD)

Who this might be right for
Psoriatic Arthritis
AbbVie 1,705
Large-scale testing (Phase 3)Study completedNCT02480153
What this trial is testing

PF-06410293 (Adalimumab-Pfizer) And Adalimumab (Humira®) In Combination With Methotrexate In Subjects With Active Rheumatoid Arthritis (REFLECTIONS B538-02).

Who this might be right for
Rheumatoid Arthritis
Pfizer 597
Large-scale testing (Phase 3)Study completedNCT04620733
What this trial is testing

RESPONSE: Response to Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Control to or an Intolerance to Ursodeoxycholic Acid (UDCA)

Who this might be right for
Primary Biliary Cholangitis
Gilead Sciences 193
Not applicableLooking for participantsNCT06899204
What this trial is testing

Real World Efficiency of Abrocitinib Treatment at Patients With Moderate to Severe Atopic Dermatitis Who Had Inadequate Response to Previous Biologic Therapies.

Who this might be right for
Atopic DermatitisAtopic Dermatitis, UnspecifiedDermatitis, Atopic
Pfizer 150
Large-scale testing (Phase 3)Ended earlyNCT01770379
What this trial is testing

Secukinumab Efficacy and Safety Study in Patients With Rheumatoid Arthritis and Inadequate Response to Anti-TNFα Agents.

Who this might be right for
Rheumatoid Arthritis
Novartis Pharmaceuticals 242
Large-scale testing (Phase 3)Study completedNCT02115750
What this trial is testing

Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Rheumatoid Arthritis (RA)

Who this might be right for
Rheumatoid Arthritis
Coherus Oncology, Inc. 647
Next Page